Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial-Reference-Cited by-同舟云学术

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Published:2016-12 Issue:12 Volume:27 Page:2196-2203
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Yoon H.H.,Bendell J.C.,Braiteh F.S.,Firdaus I.,Philip P.A.,Cohn A.L.,Lewis N.,Anderson D.M.,Arrowsmith E.,Schwartz J.D.,Gao L.,Hsu Y.,Xu Y.,Ferry D.,Alberts S.R.,Wainberg Z.A.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/12/2196/8623064/mdw423.pdf

Reference18 articles.

1. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group;Van Cutsem;J Clin Oncol,2006

2. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie;Al-Batran;J Clin Oncol,2008

3. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial;Lordick;Lancet Oncol,2013